Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
LSTA Financials LISATA THERAPEUTICS, INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $170000 | -$17M | 0.0% | -10711.2% | -$16M | — | $16M |
| 2024 | $1M | -$20M | 0.0% | -2240.9% | -$19M | — | $16M |
| 2023 | $0 | -$21M | — | — | -$20M | — | $23M |
| 2022 | $0 | -$54M | — | — | -$21M | — | $32M |
| 2021 | — | -$27M | — | — | -$22M | — | $25M |
| 2020 | — | -$8M | — | — | -$9M | — | $17M |
| 2019 | — | -$19M | — | — | -$19M | — | $14M |
| 2018 | — | -$16M | — | — | -$20M | — | $10M |
| 2017 | — | $23M | — | — | -$21M | $0 | $29M |
| 2016 | — | -$33M | — | — | -$25M | $6M | $7M |
| 2014 | — | -$55M | — | — | -$51M | $0 | $19M |
| 2013 | — | -$39M | — | — | -$30M | $3M | $46M |
| 2012 | — | -$54M | — | — | -$14M | $0 | $14M |
| 2011 | — | -$47M | — | — | -$22M | — | $4M |
| 2010 | — | -$23M | — | — | -$10M | — | $8M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$4M | — | — | -$3M | — | $13M |
| Sep '25 | $0 | -$4M | — | — | -$3M | — | $19M |
| Jun '25 | $70000 | -$5M | 0.0% | -6954.3% | -$4M | — | $17M |
| Mar '25 | $0 | -$5M | — | — | -$5M | — | $20M |
| Dec '24 | $1M | -$5M | 0.0% | -494.9% | — | — | $16M |
| Sep '24 | $0 | -$5M | — | — | -$3M | — | $20M |
| Jun '24 | $0 | -$5M | — | — | -$5M | — | $28M |
| Mar '24 | $0 | -$5M | — | — | -$7M | — | $22M |
| Dec '23 | $0 | -$5M | — | — | -$4M | — | $23M |
| Sep '23 | $0 | -$5M | — | — | -$4M | — | $32M |
| Jun '23 | $0 | -$4M | — | — | — | — | $24M |
| Mar '23 | $0 | -$6M | — | — | — | — | $28M |
| Dec '22 | $0 | -$6M | — | — | -$6M | — | $32M |
| Sep '22 | $0 | -$37M | — | — | -$4M | — | $31M |
| Jun '22 | — | -$7M | — | — | — | — | $33M |
| Mar '22 | — | -$4M | — | — | — | — | $13M |
| Dec '21 | — | -$7M | — | — | -$5M | — | $25M |
| Sep '21 | — | -$7M | — | — | -$5M | — | $13M |
| Jun '21 | — | -$6M | — | — | -$5M | — | $13M |
| Mar '21 | — | -$8M | — | — | -$8M | — | $29M |
Valuation over time
How the market has priced LSTA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 27.0× (Dec '24) to 181.6× (Jun '26).
P/S
Frequently asked questions
Is LSTA growing its revenue and profit?
See the revenue and net-income charts above for LISATA THERAPEUTICS, INC.'s multi-year trend.
How much debt does LSTA have?
As of FY2025, LISATA THERAPEUTICS, INC. reported — of total debt against $16M of cash.
What is LSTA's profit margin?
In FY2025, gross margin was —, operating margin -10711.2%, and net margin -9756.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.